11/09/2020
Program subject to change

22nd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy
October 1-4, 2020

Chairs: J. Cortes, T.P. Hughes, D.S. Krause
Co-Organizers: R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, F-X. Mahon, D. Perrotti, J. Radich, D. Réa

Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann, P. Laneuville, G. Saglio, C. Schiffer, S. Soverini, P. Valent, R. Van Etten

This program is presented according to Central European Summer Time (CEST).
Please check the corresponding hours in your time zone.

Thursday, October 1, 2020

14:00-14:10	**WELCOME**	Jorge Cortes (Augusta)
14:10-14:20	**iCMLf - A REVIEW**	Tim P. Hughes (Adélaïde)
14:20-14:53	**SPECIAL INTRODUCTORY LECTURE** **Chair:** Jerry Radich (Seattle)	
14:20-14:23	*Introduction*	
14:23-14:43	Finding relapse-fated cells at diagnosis and targeting relapse before it evolves	John Dick (Toronto)
14:43-14:53	*Discussion*	
14:53-16:40	**SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2020** **Chairs:** Brian Huntly (Cambridge), Francois -Xavier Mahon (Bordeaux)	
14:53-14:56	*Introduction*	
14:56-15:08	Targeted RNA-Based Gene Sequencing Identifies Mutated Blood Cancer-Linked Genes at Diagnosis of CML That Are Associated with Treatment Failure	Susan Branford (Adelaide)
15:08-15:20	Tgfβr - SMAD3 Signaling Protects CML and Other Myeloid Malignancies from Synthetic Lethality Triggered By PARP Inhibitor in Bone Marrow Microenvironment	Bac Viet Le (Warsaw/Philadelphia)
15:20-15:32	Interim Analysis from the Optic Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib	Jorge Cortes (Augusta)

15:32-15:44	Deceiving and Drugging BCR-ABL1 Compound Mutants: Pairing a Conformational Influencer with Asciminib or an Asciminib Proteolysis-Targeting Chimera (PROTAC)	Thomas O'Hare (Salt Lake City)
15:44-15:56	Therapeutic Inhibition of Malignant Fcγrllb-Induced BTK Activation Targets Leukemic Stem Cells in Chronic Myeloid Leukemia	Mirle Schemionek (Aachen)
15:56-16:08	Molecular Status 36 Months after TKI-Discontinuatíon in CML Is Highly Predictive for Later Loss of MMR - a Report from after−SKI.	Johan Richter (Lund)
16:08-16:20	Protein Transfer between CML and Bone Marrow Stromal Cells: Functional Meaning and the Involvement of Tnts	Marta Kolba (Warsaw)
16:20-16:40	*Discussion*	
16:40-16:50	***Break***	
16:50-17:23	**TESSA HOLYOAKE MEMORIAL LECTURE: SPECIAL LECTURE** **Chair**: Steffen Koschmieder (Aachen)	
16:50-16:53	*Introduction*	
16:53-17:13	Understanding and targeting the stem cell origins of myeloid malignancies	Ulrich Steidl (New York)
17:13-17:23	*Discussion*	
17:23-19:10	**SCIENTIFIC SESSION 2: STEM CELLS AND THE MICROENVIRONMENT** **Chairs:** Daniela Krause (Frankfurt) and Ram Thakur (Lund)	
17:23-17:26	*Introduction*	
17:26-17:41	***Keynote Presentation*** Regulation of hematopoietic stem and progenitor cells by the bone marrow microenvironment	Ralf Adams (Munster)
17:41-17:51	*Discussion*	
	Selected Abstracts	
17:51-18:03	The Role of the Autophagy Adaptor Protein PLEKHM1 in the Leukaemic Bone Marrow Microenvironment	Christina Karantanou (Frankfurt)
18:03-18:15	Features of BCR-ABL1 Driven Myeloproliferative Disease in a CML Mouse Model Are Dependent on LSC Age and Fitness	Hassan Almasoudi (Glasgow)
18:15-18:27	Murine Hematopoietic and Leukemic Stem/Progenitor Cell Lines As Model Systems for Bcr/Abl Driven Disease	Veronika Sexl (Vienna)
18:27-18:39	Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Drug-Resistant CML Stem/Progenitor Cells	Andrew Wu (Vancouver)

18:39-18:51	The Spliceosome: An Another Regulating System of Gene Expression Deregulated in CP-CML CD34+CD15- Cells	Benjamin Lebecque (Clermont-Ferrand)
18:51-19:10	*Discussion*	
19:10-19:20	**JANET ROWLEY PRIZE PRESENTATION** **Presenter:** Rob Welner (Birmingham) **Awardee 2020:** Ravi Bhatia (Birmingham)	
19:20-19:40	**JANET ROWLEY PRIZE: SPECIAL LECTURE (2)** **Chair:** Rob Welner (Birmingham)	
	The seed and the soil – the leukemia stem cell in its niche and the quest for cure	Ravi Bhatia (Birmingham)
19:40-19:50	*Discussion*	

Friday, October 2, 2020

11:30-12:15	**SCIENTIFIC SESSION 3: IMMUNOLOGY AND INFLAMMATION** **Chair:** Shinya Kimura (Saga)	
11:30-11:33	*Introduction*	
	Selected Abstracts	
11:33-11:45	Sterile Inflammation in Normal Hematopoiesis and Leukemia	Pablo Llavona (Frankfurt)
11:45-11:57	Immunosuppressive Polarization of T Cell Subsets in Spleen and Bone Marrow of Mice with CML-like Disease	Julian Swatler (Warsaw)
11:57-12:15	*Discussion*	
12:15-14:00	***Lunch***	

13:00-14:00	**SATELLITE SYMPOSIUM:** **RECENT HIGHLIGHTS IN CML: WHAT HAVE WE LEARNED IN 2020?** **Chair:** Philippe Rousselot (France) **Speakers:** Mario Tiribelli (Italy), Jorge Cortes (USA) *This educational symposium is organized and funded by Incyte Biosciences International Sàrl*

14:00-15:33	**SCIENTIFIC SESSION 4: THE BIOLOGY OF BLAST PHASE** **Chair:** Adam Mead (Oxford)	
14:00-14:03	*Introduction*	
14:03-14:18	***Keynote Presentation*** CRISPR predictions about relapse in CML	Daniel Bolon (Amherst)
14:18-14:28	*Discussion*	

Selected Abstracts

14:28-14:40	RUNX1 Mutations in Blast Phase Chronic Myeloid Leukemia	Shady Adnan-Awad (Helsinki)
14:40-14:52	H3K36ME3 Loss in Chronic Myeloid Leukemia Patients in Blast Crisis Is Mediated by an Unbalanced SETD2/KDM4A Activity and CAN be Therapeutically Targeted	Manuela Mancini (Bologna)
14:52-15:04	Releasing the Brakes on Apoptosis: Investigating Combinations of BH3 Mimetics and Nilotinib in Blast Phase CML	Narissa Parry (Glasgow)
15:04-15:16	Discovery of Novel CIP2A Variant (NOCIVA) and its Clinical Association with Myeloid Leukemias	Eleonora Mäkelä (Turku)
15:16-15:33	*Discussion*	

15:35 ***Biology Posters - Mentored Poster Walk 1***
Biology Poster Walk Leaders: Sin Tiong Ong (Singapore), Stéphane Prost (Fontenay-aux-Roses)

15:35 – 16:35 **CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)**

Clinical trial design	Donald Berry (Houston) and Joëlle Guilhot (Poitiers)
New drugs under development	Jorge Cortes (Augusta) and Tim Hughes (Adelaide)
Understanding and analyzing the new ELN recommendations	Andreas Hochhaus (Jena) and Michael Mauro (New York)

16:35-16:45 ***Convene in the Main Conference Hall***

16:45 -18:20 **SPECIAL SYMPOSIUM ON ONCOIMMUNOLOGY IN HEMATOLOGIC MALIGNANCIES**
Chairs: Jorge Cortes (Augusta), Kimmo Porkka (Helsinki)

16:45-16:55	Introductory overview – concepts and challenges	
16:55-17:07	*Leukemia vaccines*	David Scheinberg (New York)
17:07-17:19	*CAR-T for myeloid malignancies*	Saar Gill (Philadelphia)
17:19-17:31	*Bi-specific and allogeneic CAR-T*	Xianxin Hua (Philadelphia)
17:31-17:43	*Checkpoint inhibitors*	Justin Kline (Chicago)
17:43-17:55	*Bispecific antibodies in myeloid leukemias*	Roland Walter (Seattle)
17:55-18:20	General Discussion	

18:20-18:53	**SPECIAL LECTURE (3):** **Chair:** Rick Van Etten (Irvine)	
18:20-18:23	*Introduction*	
18:23-18:43	CML blast crisis and the microenvironment	Tannishtha Reya (San Diego)
18:43-18:53	*Discussion*	

18:55 – 19:55	**CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)**	
	Hematopoiesis	Timm Schroeder (Basel)
	Immunological approaches to the treatment of leukemia	Roland Walter (Seattle) and David Scheinberg (New York)

Saturday, October 3, 2020

08:50-10:50	**WORKSHOP FOR NON-CLINICAL SCIENTISTS #1** **PROTEOMICS / SECRETOMICS** **Chairs:** Oliver Hantschel (Marburg) and Vignir Helgason (Glasgow)	
08:50-08:55	Introduction	Oliver Hantschel (Marburg) and Vignir Helgason (Glasgow)
08:55-09:20	An integrated platform for biomarker and drug target discovery using proteomics	Anthony Whetton (Manchester)
09:20-09:45	MS-proteomics to uncover the complexity and function of the cell secretome	Sara Zanivan (Glasgow)
09:45-10:10	Title: TBA	Oliver Schilling (Freiburg)
10:10-10:40	*Discussion*	
10:40-10:50	Conclusion	

11:00-11:10	**JOHN GOLDMAN PRIZE PRESENTATION** **Presenter:** Hemant Malhotra (Jaipur) **Awardee 2020:** Jane Apperley (London)	
11:10-11:30	**JOHN GOLDMAN PRIZE: SPECIAL LECTURE (4)** **Chair:** Hemant Malhotra (Jaipur)	
	CML and me: reflections on the roadmap to cure	Jane Apperley (London)
11:30-11:40	*Discussion*	

11:40-13:10	**SCIENTIFIC SESSION 5: NEW TREATMENT STRATEGIES** **Chair:** Gianantonio Rosti (Bologna)	
11:40-11:43	*Introduction*	
11:43-11:58	***Keynote Presentation*** Citius, Altius, Fortius ?	Andreas Hochhaus (Jena)
11:58-12:08	*Discussion*	
	Selected Abstracts	
12:08-12:20	A Novel Oral Demethylating Agent, or-2100, in Combination with Tyrosine Kinase Inhibitors Overcomes Resistance in Chronic Myeloid Leukemia	Kazuharu Kamachi (Saga)
12:20-12:32	Targeting Integrated Stress Response Combined with Imatinib As a Novel Strategy to Eradicate Imatinib-Resistant CML Cells	Katarzyna Piwocka (Warsaw)
12:32-12:44	Activity of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) in CML Patients Failing TKI Therapies Including Ponatinib	Jorge Cortes (Augusta)
12:44-12:56	Radotinib Treatment for Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to or Intolerant of BCR-ABL1 Tyrosine-Kinase Inhibitors: 60-Month Follow-up of a Phase 2 Study	Sung-Hyun Kim (Busan)
12:56-13:10	*Discussion*	
13:10-14:50	***Lunch***	

13:20-14:50	**SATELLITE SYMPOSIUM:** **TRAVELING THROUGH THE UNSOLVED NEEDS IN CML: TOWARDS NEW STRATEGIES** **Chair:** Andreas Hochhaus (Jena) **Speakers:** Valentin Garcia-Gutiérrez (Madrid), Massimo Breccia (Roma), Delphine Réa (Paris) *This educational symposium is organized and funded by Novartis Oncology*

14:50-15:00	***Convene in the Main Conference Hall***
15:00-15:20	**ESH INTERNATIONAL JOHN GOLDMAN RESEARCH AWARD CEREMONY**
15:00-15:10	**Presenter:** Hervé Dombret (Paris), ESH President
15:10-15:20	**Awardee 2020:** Vaidehi Krishnan (Singapore) High dimensional single-cell analysis to predict TFR at the time of CML diagnosis

15:20-16:55	**SCIENTIFIC SESSION 6: TREATMENT-FREE REMISSION** **Chair:** Dragana Milojkovic (London)	
15:20-15:23	*Introduction*	
15:23-15:38	***Keynote Presentation*** Strategies for optimal TFR rates in CML	Susanne Saussele (Mannheim)
15:38-15:48	*Discussion*	
	Selected Abstracts	
15:48-16:00	The rate of *BCR-ABL1* decline after TKI commencement is a strong predictor of sustained Treatment Free Remission	Naranie Shanmuganathan (Adelaide)
16:00-16:12	High Level of Successful TKI Discontinuation Outside Clinical Trials - a Population-Based Study from the Swedish CML Registry	Johan Richter (Lund)
16:12-16:24	Efficacy and Safety of Pioglitazone in a Phase II Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia Patients	Katia Pagnano (Campinas)
16:24-16:36	Update of the French Spirit Trial with a Detailed Focus on Treatment Free Remission	François Guilhot (Poitiers)
16:36-16:55	*Discussion*	
16:55-17:05	***Break***	
17:05-18:50	**SCIENTIFIC SESSION 7: TREATMENT-FREE REMISSION - PREDICTIVE FACTORS** **Chair:** Delphine Rea (Paris)	
17:05-17:08	*Introduction*	
17:08-17:23	***Keynote Presentation*** Successful TFR in CML: is it predictable?	Agnes Yong (Adelaide)
17:23-17:33	*Discussion*	
	Selected Abstracts	
17:33-17:45	BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Early Predictive Surrogate for Treatment-Free Remission Failure after Imatinib Discontinuation	Dennis Kim (Toronto)
17:45-17:57	Chronic Myeloid Leukemia Patients' Concerns during Phase I of the Treatment-Free Remission Journey: Considerations Between Patients and Doctors in the Different CML Advocates Network Regions	Giora Sharf (Netanya)
17:57-18:09	Best Duration of Deep Molecular Remission to Achieve Therapy-Free Remission in Chronic Myeloid Leukaemia	Robert Gale (London)

18:09-18:21	Risk Factor Analysis for Treatment-Free Remission Failure after Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia in Chronic Phase: The Optimal Duration of Total Imatinib Treatment and MR4 Response	Dennis Kim (Toronto)
18:21-18:33	Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study	Frédéric Millot (Poitiers)
18:33-18:50	*Discussion*	
18:50-19:23	**SPECIAL LECTURE (5):** **Chair:** Giovanni Martinelli (Meldola)	
18:50-18:53	*Introduction*	
18:53-19:13	Human evolutionary genomic medicine	Melissa Ilardo (Salt Lake City)
19:13-19:23	*Discussion*	

Sunday, October 4, 2020

14:30-16:30	**WORKSHOP FOR NON-CLINICAL SCIENTISTS #2** **ARTIFICIAL INTELLIGENCE / MACHINE LEARNING** **Chairs:** Michael Deininger (Salt Lake City) and Daniela Krause (Frankfurt)	
14:30-14:35	Introduction	Michael Deininger (Salt Lake City) and Daniela Krause (Frankfurt)
14:35-15:00	Long-term single-cell quantification: new tools for old questions	Timm Schroeder (Basel)
15:00-15:25	Computational Pathology: Towards Precision Medicine	Andrew Janowczyk (Cleveland)
15:25-15:50	Learning to Care: Artificial Intelligence Meets Clinical Practice	Jeffrey Humpherys (Salt Lake City)
15:50-16:20	Discussion	
16:20-16:30	Conclusion	

15:30-16:30	***Clinical Posters - Mentored Poster Walk 2*** **Clinical Poster Walk Leaders:** Franck Nicolini (Lyon), Pierre Laneuville (Montreal)	
16:30- 17:03	**SPECIAL LECTURE (6):** **Chair**: Catriona Jamieson (La Jolla)	
16:30-16:33	*Introduction*	
16:33-16:53	Single cell RNA sequencing in MPN	Bethan Psaila (Oxford)
16:53-17:03	*Discussion*	

17:03-18:20	**DEBATE: "SWITCH TO A MORE POTENT DRUG TO GAIN ELIGIBILITY FOR TFR?"** **Chair:** Philippe Rousselot (Versailles)	
17:03-17:06	*Introduction*	
17:06-17:10	Voting	
17:10-17:30	Against:	Charles Schiffer (Detroit)
17:30-17:50	For:	Giuseppe Saglio (Turin)
17:50-18:20	Voting and Discussion	
18:20-18:30	**iCMLf PRIZE PRESENTATION:** **Presenter:** Jerry Radich (Seattle) **Awardee 2020:** Sabira Kurtovic (Sarajevo)	
18:30-18:50	**iCMLf PRIZE: SPECIAL LECTURE (7)** **Chair:** Jerry Radich (Seattle)	
	CML management in war and peace: lessons that shaped future approaches	Sabira Kurtovic (Sarajevo)
18:50-19:00	*Discussion*	
19:00-20:20	**SCIENTIFIC SESSION 8: TKI SAFETY** **Chair:** Javier Pinilla-Ibarz (Tampa)	
19:00-19:03	*Introduction*	
19:03-19:18	**Keynote presentation** Novel trial designs	Donald Berry (Houston)
19:18-19:28	*Discussion*	
	Selected Abstracts	
19:28-19:40	Cellular Metabolic Flexibility to Explain Interindividual Susceptibility for Tyrosine Kinase Inhibitor-Induced Muscle Complaints	Lando Janssen (Nijmegen)
19:40-19:52	Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia	James Januzzi (Boston)
19:52-20:04	High Body Mass Index (BMI) and Treatment Responses in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Receiving First-Line Dasatinib or Imatinib: Exploratory Post Hoc Analysis of the Phase 3 DASISION Study	Massimo Breccia (Rome)
20:04-20:20	*Discussion*	
20:20	***Closing remarks***	